Trimodally treatment for stage IIIa NSCLC patients increases survival while not effecting surgical mortality or complexity

Dan Aravot, Yaron D. Barac, Efrat Krutzwald-Josefson, Aaron M. Allen, Dov Flex, Nir Peled, Mordechai R. Kramer, Yuri Peysakhovich, Milton Saute

Research output: Contribution to journalArticlepeer-review


INTRODUCTION: Advanced non-small cell lung cancer (NSCLC) is still a therapeutic challenge as the 5-year survival is under 30%. The optimal treatment regimen is still under debate. HYPOTHESIS: Neo adjuvant (NA) treatment given pre-pneumonectomy does not increase surgical complexity or peri-OP mortality while it has a potential to increase long term survival. METHODS: We have conducted a retrospective study of 169 patients who underwent a pneumonectomy for NSCLC between January 2005 to December 2015 and focused on stage IIIa patients; a cohort of 51 patients, 30 which received neo adjuvant chemo-radiation (NA group) prior to pneumonectomy and 21 patients who had undergone pneumonectomy followed by adjuvant treatment (Adjuvant group). Surgical complexity and short- and long-term survival were evaluated. Surgical complexity was assessed by surrogates as surgery duration, hospitalization length and interdepartmental transfer. RESULTS: While no statistically significant differences were found in surgery duration, hospitalization length, morbidity in the 1st year post-OP and the peri-OP mortality; The long term beneficiary effect among the neo adjuvant patients was clear; while 30% of the NA patients were alive 8 years post-OP, there were no survivors in the adjuvant group 5.5 years post-OP. CONCLUSION: We conclude that while NA treatment has no effect on operation complexity, peri-OP mortality or post-OP morbidity; its impact on long term survival is protuberant, therefore, we believe that NA treatment should be considered as the treatment of choice in advanced NSCLC in need for pneumonectomy.

Original languageEnglish
Pages (from-to)7
Number of pages1
JournalJournal of Cardiothoracic Surgery
Issue number1
StatePublished - 9 Jan 2019


  • Chemo-radiation
  • Neo adjuvant therapy
  • Pneumonectomy


Dive into the research topics of 'Trimodally treatment for stage IIIa NSCLC patients increases survival while not effecting surgical mortality or complexity'. Together they form a unique fingerprint.

Cite this